Clinical trials: Cancer
HIV Infections, Breast Cancer
The MARVIN Chatbots to Provide Information for Different Health Conditions
This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists).
- Conditions
- HIV Infections, Breast Cancer, Pediatric Emergency Medicine
- Trial name
- NCT05789901
- Testing
- MARVIN, MARVIN-Pharma, MARVINA
- Where
- 2 sites in Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Colorectal Cancer
Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC
This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died…
- Trial name
- NCT03564912
- Testing
- Capecitabine Oral Tablet [Xeloda]
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang University
Lymphoma, T-Cell, Peripheral
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of PTCL can predict disease progression
- Trial name
- NCT03051581
- Testing
- 18F-FDG PET/ CT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Cancer Hospital & Institute
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic kidney cancer that has not responded to previous therapy with interleukin-2.
- Trial name
- NCT00009919
- Testing
- semaxanib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Paraganglioma, Pheochromocytoma
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Hereditary paraganglioma -due to SDH (SDHD, SDHB, SDHC) germline mutations- causes paragangliomas and pheochromocytomas. Presymptomatic genetic testing should be offered to all first-degree relatives if an SDH mutation is…
- Trial name
- NCT00188019
- Testing
- diagnosis methods
- Where
- France
- Volunteers
- 248 people
- Sponsor
- University Hospital, Angers
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor
Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in early first complete remission improves the long-term outcomes for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Tyrosine Kinase Inhibitor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT03624530
- Testing
- Tyrosine kinase inhibitor (TKIs)
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metabolic Syndrome, Prostate Cancer
Effect of TyG Index on Outcomes of Radical Prostatectomy
We investigate the association between Triglyserid-Glucose(TyG) index and prostate cancer in patients undergoing radical prostatectomy.
- Conditions
- Metabolic Syndrome, Prostate Cancer, Insulin Resistance
- Trial name
- TyG-PCa (NCT03447028)
- Volunteers
- 200 people
- Sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
Cancer, Covid19
CCP Cancer UK Companion Study
Currently, there is extremely limited information regarding the risks posed by SARS-CoV-2 to patients with cancer. This study aims to understand the presentation, management and outcomes of patients with cancer.
- Trial name
- NCT04603105
- Where
- United Kingdom
- Volunteers
- 9,000 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Medulloblastoma
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
- Trial name
- NCT04696029
- Testing
- Difluoromethylornithine
- Where
- 26 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Giselle Sholler
Osteosarcoma, Paget's Disease
Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
The objective of these studies is to use changes in 3 Tesla MRI measurements of tumor protein content, cell density, and microvessel perfusion, obtained before and after a single cycle of NAC, to predict eventual tumor response…
- Conditions
- Osteosarcoma, Paget's Disease, Ewing Sarcoma
- Trial name
- NCT01882231
- Testing
- DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pain, Cancer
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.
- Trial name
- NCT00263575
- Testing
- EN3267
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Metastatic Bone Tumor
Automated Detection of Metastatic Bone Disease on Bone Scintigraphy Scans
Bone scintigraphy scans are two dimensional medical images that are used heavily in nuclear medicine. The scans detect changes in bone metabolism with high sensitivity, yet it lacks the specificity to underlying causes.
- Trial name
- NCT05110430
- Testing
- Deep learning based detection of metastatic bone disease on bone scintigraphy scans.
- Where
- Netherlands
- Volunteers
- 2,365 people
- Sponsor
- Maastricht University
Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive.
- Trial name
- NCT03383965
- Testing
- ICAR30 T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Immune Cell, Inc.
Acanthosis Nigricans, Polycystic Ovary Syndrome
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome
OBJECTIVES: I. Evaluate insulin resistance in thin and obese hyperandrogenic women with polycystic ovarian disease or hyperandrogenism insulin resistance acanthosis nigricans syndrome and in thin and obese controls, using an…
- Trial name
- NCT00004311
- Testing
- leuprolide acetate, spironolactone
- Sponsor
- National Center for Research Resources (NCRR)
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Bone Tumor, Bone Cancer
Medical Payment Case Management for Financial Toxicity in Patients With Primary Bone Tumors: A Randomized Controlled Trial
The goal of this clinical trial is to learn if adding a medical payment case management service to the hospital's usual follow-up care can reduce the financial hardship of cancer treatment in patients of any age, including…
- Trial name
- NCT07888244
- Testing
- Medical payment case management service
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Shanghai 6th People's Hospital
All Malignancies, Children Being Treated for Catastrophic Illness
Pharmacogenetic Determinants Of Treatment Response In Children
To investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates.
- Trial name
- NCT00730678
- Where
- United States
- Volunteers
- 8,800 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Fallopian Tube Cancer, Ovarian Cancer
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CT-2103 in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00017017
- Testing
- paclitaxel poliglumex
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Merkel Cell Carcinoma
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
Merkel cell carcinoma (MCC) is a rare aggressive skin carcinoma. Approximately 80% of MCC are related to the Merkel Cell Polyomavirus (MCPyV). Although rates of relapse are high, the follow-up strategy lacks consensus.
- Trial name
- SUMMERTIME (NCT04705389)
- Testing
- Samples
- Where
- 10 sites in Austria, Finland and 8 more
- Volunteers
- 35 people
- Sponsor
- University Hospital, Tours
Melanoma (Skin), Neuroblastoma
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing.
- Conditions
- Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003750
- Testing
- hu14.18-IL2 fusion protein
- Where
- 59 sites in United States, Australia and 1 more
- Volunteers
- 28 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.